| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Leukemia, Myeloid, Acute | 38 | 2023 | 763 | 5.330 |
Why?
|
| Myeloproliferative Disorders | 13 | 2023 | 110 | 4.970 |
Why?
|
| Myelodysplastic Syndromes | 22 | 2024 | 346 | 4.450 |
Why?
|
| Primary Myelofibrosis | 13 | 2021 | 56 | 2.470 |
Why?
|
| Azacitidine | 12 | 2023 | 137 | 2.040 |
Why?
|
| Hematopoietic Stem Cell Transplantation | 21 | 2023 | 878 | 1.890 |
Why?
|
| Antineoplastic Agents | 22 | 2023 | 2358 | 1.760 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 27 | 2024 | 2436 | 1.600 |
Why?
|
| Protein Kinase Inhibitors | 11 | 2023 | 589 | 1.520 |
Why?
|
| Hematologic Neoplasms | 12 | 2022 | 329 | 1.480 |
Why?
|
| Transplantation Conditioning | 18 | 2020 | 373 | 1.410 |
Why?
|
| Stem Cell Transplantation | 5 | 2018 | 183 | 1.380 |
Why?
|
| Leukemia, Myelomonocytic, Chronic | 4 | 2024 | 21 | 1.360 |
Why?
|
| Sulfonamides | 5 | 2022 | 300 | 1.230 |
Why?
|
| Pyrimidines | 12 | 2023 | 370 | 1.190 |
Why?
|
| Blast Crisis | 4 | 2023 | 33 | 1.160 |
Why?
|
| Benzamides | 7 | 2020 | 229 | 1.130 |
Why?
|
| Mitoxantrone | 5 | 2020 | 68 | 1.120 |
Why?
|
| Mutation | 18 | 2023 | 3967 | 1.000 |
Why?
|
| Histone Deacetylase Inhibitors | 5 | 2023 | 85 | 0.990 |
Why?
|
| Isocitrate Dehydrogenase | 3 | 2021 | 51 | 0.960 |
Why?
|
| Bridged-Ring Compounds | 2 | 2020 | 13 | 0.930 |
Why?
|
| Aminopyridines | 2 | 2021 | 38 | 0.920 |
Why?
|
| Triazines | 2 | 2021 | 53 | 0.910 |
Why?
|
| Humans | 113 | 2024 | 86617 | 0.880 |
Why?
|
| Transplantation, Homologous | 19 | 2020 | 996 | 0.860 |
Why?
|
| Cytarabine | 9 | 2023 | 218 | 0.850 |
Why?
|
| Janus Kinase 2 | 7 | 2021 | 57 | 0.810 |
Why?
|
| Janus Kinase Inhibitors | 1 | 2020 | 19 | 0.760 |
Why?
|
| Pyrrolidines | 1 | 2020 | 58 | 0.750 |
Why?
|
| Aged | 56 | 2023 | 18402 | 0.750 |
Why?
|
| Enzyme Inhibitors | 3 | 2021 | 639 | 0.730 |
Why?
|
| Depsipeptides | 2 | 2010 | 29 | 0.720 |
Why?
|
| Antibiotics, Antineoplastic | 2 | 2010 | 114 | 0.690 |
Why?
|
| Treatment Outcome | 34 | 2024 | 7990 | 0.690 |
Why?
|
| Leukemia | 6 | 2022 | 320 | 0.660 |
Why?
|
| Middle Aged | 55 | 2023 | 25017 | 0.660 |
Why?
|
| Disease Management | 5 | 2020 | 327 | 0.640 |
Why?
|
| fms-Like Tyrosine Kinase 3 | 7 | 2023 | 127 | 0.640 |
Why?
|
| DNA Modification Methylases | 1 | 2017 | 25 | 0.630 |
Why?
|
| Neoplasms | 9 | 2023 | 2898 | 0.600 |
Why?
|
| Male | 62 | 2024 | 40958 | 0.590 |
Why?
|
| Benzimidazoles | 2 | 2019 | 140 | 0.590 |
Why?
|
| Mitogen-Activated Protein Kinase Kinases | 2 | 2015 | 101 | 0.580 |
Why?
|
| Aged, 80 and over | 27 | 2020 | 6501 | 0.580 |
Why?
|
| Pyrazoles | 5 | 2020 | 153 | 0.560 |
Why?
|
| Hydroxamic Acids | 2 | 2017 | 49 | 0.540 |
Why?
|
| Leukemia, Myelogenous, Chronic, BCR-ABL Positive | 5 | 2012 | 173 | 0.530 |
Why?
|
| Molecular Targeted Therapy | 4 | 2020 | 266 | 0.510 |
Why?
|
| Female | 60 | 2024 | 44509 | 0.500 |
Why?
|
| Precision Medicine | 4 | 2021 | 395 | 0.490 |
Why?
|
| Disease Progression | 8 | 2020 | 1531 | 0.480 |
Why?
|
| Eosinophilia | 2 | 2014 | 84 | 0.450 |
Why?
|
| Cell Transformation, Neoplastic | 2 | 2015 | 427 | 0.450 |
Why?
|
| Cord Blood Stem Cell Transplantation | 4 | 2016 | 93 | 0.450 |
Why?
|
| Hematopoiesis, Extramedullary | 1 | 2013 | 12 | 0.450 |
Why?
|
| Pulmonary Eosinophilia | 1 | 2012 | 4 | 0.450 |
Why?
|
| Receptor, Platelet-Derived Growth Factor alpha | 1 | 2012 | 11 | 0.450 |
Why?
|
| Bone Marrow Neoplasms | 1 | 2012 | 17 | 0.450 |
Why?
|
| Core Binding Factors | 2 | 2011 | 12 | 0.440 |
Why?
|
| Cough | 1 | 2012 | 54 | 0.440 |
Why?
|
| Thrombocytopenia | 6 | 2023 | 183 | 0.430 |
Why?
|
| Dyspnea | 1 | 2012 | 73 | 0.430 |
Why?
|
| Epigenomics | 2 | 2023 | 100 | 0.420 |
Why?
|
| Uridine | 3 | 2021 | 56 | 0.420 |
Why?
|
| Gene Rearrangement | 1 | 2012 | 170 | 0.420 |
Why?
|
| Adult | 41 | 2024 | 25640 | 0.400 |
Why?
|
| Mutation, Missense | 1 | 2013 | 276 | 0.400 |
Why?
|
| Remission Induction | 10 | 2022 | 722 | 0.390 |
Why?
|
| Genomics | 4 | 2022 | 720 | 0.380 |
Why?
|
| Genes, ras | 3 | 2019 | 96 | 0.380 |
Why?
|
| Stem Cells | 1 | 2013 | 351 | 0.370 |
Why?
|
| Graft vs Host Disease | 8 | 2020 | 365 | 0.370 |
Why?
|
| Thrombocythemia, Essential | 3 | 2021 | 14 | 0.360 |
Why?
|
| Janus Kinases | 3 | 2020 | 23 | 0.350 |
Why?
|
| Recurrence | 9 | 2021 | 1139 | 0.350 |
Why?
|
| Electromagnetic Fields | 1 | 2008 | 26 | 0.340 |
Why?
|
| Pyridines | 3 | 2021 | 310 | 0.340 |
Why?
|
| Prognosis | 11 | 2023 | 3675 | 0.330 |
Why?
|
| Chromosome Aberrations | 5 | 2023 | 387 | 0.330 |
Why?
|
| Telomerase | 2 | 2021 | 55 | 0.330 |
Why?
|
| Naphthyridines | 2 | 2021 | 53 | 0.320 |
Why?
|
| Pyridones | 3 | 2022 | 51 | 0.300 |
Why?
|
| Polycythemia Vera | 3 | 2013 | 23 | 0.300 |
Why?
|
| Piperazines | 5 | 2014 | 272 | 0.300 |
Why?
|
| Antimetabolites, Antineoplastic | 3 | 2017 | 236 | 0.290 |
Why?
|
| DNA Repair | 1 | 2008 | 356 | 0.290 |
Why?
|
| Leukemia, Lymphocytic, Chronic, B-Cell | 3 | 2015 | 136 | 0.280 |
Why?
|
| Risk Factors | 6 | 2023 | 5417 | 0.270 |
Why?
|
| Oligonucleotides | 3 | 2021 | 92 | 0.270 |
Why?
|
| Geriatric Assessment | 2 | 2019 | 166 | 0.270 |
Why?
|
| Medical Oncology | 3 | 2021 | 359 | 0.270 |
Why?
|
| Leukemia, Myeloid | 3 | 2014 | 249 | 0.270 |
Why?
|
| Maximum Tolerated Dose | 5 | 2016 | 270 | 0.260 |
Why?
|
| Disease Susceptibility | 2 | 2020 | 193 | 0.260 |
Why?
|
| Epigenesis, Genetic | 4 | 2014 | 479 | 0.260 |
Why?
|
| Cladribine | 1 | 2004 | 35 | 0.250 |
Why?
|
| Imatinib Mesylate | 5 | 2014 | 126 | 0.240 |
Why?
|
| Survival Analysis | 11 | 2020 | 1538 | 0.240 |
Why?
|
| Oleic Acids | 1 | 2023 | 26 | 0.240 |
Why?
|
| Haplotypes | 3 | 2016 | 642 | 0.230 |
Why?
|
| Dose-Response Relationship, Drug | 8 | 2019 | 1961 | 0.230 |
Why?
|
| Antibodies, Monoclonal, Humanized | 7 | 2020 | 930 | 0.230 |
Why?
|
| Deoxycytidine | 1 | 2004 | 237 | 0.230 |
Why?
|
| Hematology | 1 | 2023 | 29 | 0.230 |
Why?
|
| Young Adult | 15 | 2024 | 5974 | 0.220 |
Why?
|
| Myelodysplastic-Myeloproliferative Diseases | 1 | 2022 | 9 | 0.220 |
Why?
|
| Cytogenetic Analysis | 3 | 2011 | 71 | 0.220 |
Why?
|
| Socioeconomic Factors | 2 | 2024 | 567 | 0.220 |
Why?
|
| Oncogene Proteins, Fusion | 2 | 2014 | 128 | 0.220 |
Why?
|
| Clinical Trials as Topic | 3 | 2020 | 1169 | 0.220 |
Why?
|
| Precursor T-Cell Lymphoblastic Leukemia-Lymphoma | 1 | 2023 | 53 | 0.220 |
Why?
|
| Adenine Nucleotides | 2 | 2013 | 63 | 0.220 |
Why?
|
| Arabinonucleosides | 2 | 2013 | 39 | 0.220 |
Why?
|
| Proto-Oncogene Proteins c-kit | 2 | 2013 | 79 | 0.210 |
Why?
|
| Biomarkers, Tumor | 3 | 2020 | 1464 | 0.210 |
Why?
|
| Antibodies, Neoplasm | 4 | 2010 | 84 | 0.210 |
Why?
|
| Pneumonia | 1 | 2024 | 179 | 0.210 |
Why?
|
| Peripheral Blood Stem Cell Transplantation | 2 | 2012 | 67 | 0.200 |
Why?
|
| Neoplasm Recurrence, Local | 5 | 2015 | 1313 | 0.200 |
Why?
|
| Antigens, CD34 | 5 | 2017 | 158 | 0.200 |
Why?
|
| Prospective Studies | 6 | 2023 | 4212 | 0.200 |
Why?
|
| Administration, Oral | 4 | 2019 | 684 | 0.190 |
Why?
|
| Glycine | 1 | 2021 | 92 | 0.190 |
Why?
|
| Clonal Evolution | 1 | 2020 | 15 | 0.190 |
Why?
|
| Biomedical Research | 2 | 2021 | 375 | 0.190 |
Why?
|
| Kaplan-Meier Estimate | 6 | 2020 | 860 | 0.180 |
Why?
|
| DNA Methylation | 4 | 2020 | 628 | 0.180 |
Why?
|
| CD8-Positive T-Lymphocytes | 1 | 2023 | 559 | 0.180 |
Why?
|
| Etoposide | 1 | 2020 | 196 | 0.180 |
Why?
|
| Precursor Cell Lymphoblastic Leukemia-Lymphoma | 1 | 2024 | 375 | 0.180 |
Why?
|
| Allografts | 2 | 2017 | 172 | 0.180 |
Why?
|
| MAP Kinase Kinase 2 | 1 | 2019 | 14 | 0.170 |
Why?
|
| Unrelated Donors | 2 | 2017 | 50 | 0.170 |
Why?
|
| Fetal Blood | 2 | 2017 | 90 | 0.170 |
Why?
|
| MAP Kinase Kinase 1 | 1 | 2019 | 36 | 0.170 |
Why?
|
| Interdisciplinary Communication | 1 | 2019 | 130 | 0.170 |
Why?
|
| Philadelphia Chromosome | 1 | 2018 | 38 | 0.170 |
Why?
|
| Immunotherapy | 3 | 2015 | 629 | 0.160 |
Why?
|
| Animals | 9 | 2023 | 26582 | 0.160 |
Why?
|
| Proto-Oncogene Proteins c-akt | 1 | 2019 | 322 | 0.150 |
Why?
|
| Preoperative Care | 1 | 2019 | 394 | 0.150 |
Why?
|
| Patient Care Team | 1 | 2019 | 280 | 0.150 |
Why?
|
| Neutropenia | 4 | 2022 | 215 | 0.150 |
Why?
|
| Biomarkers | 2 | 2020 | 1718 | 0.150 |
Why?
|
| Hematopoietic Stem Cells | 2 | 2016 | 292 | 0.140 |
Why?
|
| Pyrimidinones | 2 | 2019 | 36 | 0.140 |
Why?
|
| Haploidy | 1 | 2016 | 31 | 0.140 |
Why?
|
| Maleimides | 1 | 2016 | 29 | 0.140 |
Why?
|
| Heterocyclic Compounds, 3-Ring | 1 | 2016 | 26 | 0.140 |
Why?
|
| Antibodies, Monoclonal | 4 | 2010 | 1376 | 0.140 |
Why?
|
| Nitriles | 4 | 2020 | 149 | 0.140 |
Why?
|
| Melphalan | 3 | 2011 | 97 | 0.140 |
Why?
|
| Drug Resistance, Neoplasm | 3 | 2023 | 592 | 0.140 |
Why?
|
| Glycogen Synthase Kinase 3 | 1 | 2016 | 63 | 0.140 |
Why?
|
| Karyotype | 1 | 2015 | 33 | 0.130 |
Why?
|
| Niacinamide | 1 | 2015 | 116 | 0.130 |
Why?
|
| Cyclin-Dependent Kinase Inhibitor p15 | 1 | 2014 | 24 | 0.130 |
Why?
|
| Salvage Therapy | 2 | 2007 | 233 | 0.130 |
Why?
|
| Vidarabine | 3 | 2010 | 141 | 0.130 |
Why?
|
| Quinolones | 2 | 2005 | 60 | 0.130 |
Why?
|
| Graft Survival | 3 | 2016 | 884 | 0.130 |
Why?
|
| Thiazoles | 1 | 2015 | 131 | 0.130 |
Why?
|
| Cyclin-Dependent Kinase Inhibitor p21 | 1 | 2014 | 74 | 0.130 |
Why?
|
| HLA Antigens | 1 | 2016 | 232 | 0.120 |
Why?
|
| Molecular Biology | 1 | 2015 | 89 | 0.120 |
Why?
|
| Receptor, Platelet-Derived Growth Factor beta | 1 | 2014 | 28 | 0.120 |
Why?
|
| Acute Disease | 5 | 2022 | 826 | 0.120 |
Why?
|
| Drug Monitoring | 2 | 2020 | 118 | 0.120 |
Why?
|
| Signal Transduction | 2 | 2023 | 3241 | 0.120 |
Why?
|
| Chronic Disease | 3 | 2007 | 971 | 0.120 |
Why?
|
| Indoles | 1 | 2015 | 318 | 0.120 |
Why?
|
| Neoplasm Staging | 3 | 2015 | 1937 | 0.120 |
Why?
|
| Blood Platelets | 1 | 2013 | 149 | 0.110 |
Why?
|
| mRNA Cleavage and Polyadenylation Factors | 1 | 2012 | 2 | 0.110 |
Why?
|
| Phthalazines | 1 | 2013 | 39 | 0.110 |
Why?
|
| Drug Administration Schedule | 4 | 2015 | 916 | 0.110 |
Why?
|
| Quality of Life | 3 | 2023 | 1583 | 0.110 |
Why?
|
| CD40 Antigens | 1 | 2012 | 43 | 0.110 |
Why?
|
| Genes, Neoplasm | 1 | 2012 | 37 | 0.110 |
Why?
|
| Alemtuzumab | 5 | 2011 | 83 | 0.110 |
Why?
|
| Cell Line, Tumor | 3 | 2023 | 2426 | 0.110 |
Why?
|
| Hematopoiesis | 1 | 2013 | 163 | 0.110 |
Why?
|
| Up-Regulation | 1 | 2014 | 712 | 0.100 |
Why?
|
| Disease-Free Survival | 5 | 2015 | 1204 | 0.100 |
Why?
|
| Amino Acid Substitution | 1 | 2013 | 339 | 0.100 |
Why?
|
| Steroids | 1 | 2012 | 177 | 0.100 |
Why?
|
| Mice, Inbred NOD | 2 | 2022 | 187 | 0.100 |
Why?
|
| Antimitotic Agents | 1 | 2011 | 3 | 0.100 |
Why?
|
| Thionucleotides | 2 | 2008 | 56 | 0.100 |
Why?
|
| CCAAT-Enhancer-Binding Proteins | 1 | 2011 | 34 | 0.100 |
Why?
|
| Comorbidity | 4 | 2018 | 943 | 0.100 |
Why?
|
| Neoplasms, Second Primary | 2 | 2012 | 252 | 0.100 |
Why?
|
| Consensus | 2 | 2023 | 335 | 0.100 |
Why?
|
| Lymphoma, T-Cell, Cutaneous | 1 | 2010 | 12 | 0.100 |
Why?
|
| Karyotyping | 1 | 2011 | 250 | 0.100 |
Why?
|
| Myeloid-Lymphoid Leukemia Protein | 1 | 2011 | 72 | 0.100 |
Why?
|
| Fusion Proteins, bcr-abl | 2 | 2008 | 107 | 0.100 |
Why?
|
| Recombinant Proteins | 3 | 2012 | 1014 | 0.100 |
Why?
|
| Dioxygenases | 1 | 2011 | 74 | 0.100 |
Why?
|
| Hepatic Veno-Occlusive Disease | 1 | 2010 | 19 | 0.100 |
Why?
|
| Busulfan | 1 | 2010 | 39 | 0.100 |
Why?
|
| Renal Insufficiency | 1 | 2011 | 114 | 0.100 |
Why?
|
| Tumor Suppressor Protein p53 | 2 | 2023 | 381 | 0.100 |
Why?
|
| Mice | 5 | 2023 | 11352 | 0.090 |
Why?
|
| Gene Expression | 1 | 2014 | 1284 | 0.090 |
Why?
|
| Adolescent | 7 | 2024 | 8979 | 0.090 |
Why?
|
| Terminal Care | 1 | 2011 | 130 | 0.090 |
Why?
|
| Cohort Studies | 3 | 2016 | 2767 | 0.090 |
Why?
|
| Histone-Lysine N-Methyltransferase | 1 | 2011 | 154 | 0.090 |
Why?
|
| Graft Rejection | 1 | 2016 | 1065 | 0.090 |
Why?
|
| United States | 5 | 2024 | 6665 | 0.090 |
Why?
|
| Myeloid Cells | 1 | 2010 | 98 | 0.090 |
Why?
|
| Protein Processing, Post-Translational | 2 | 2023 | 371 | 0.090 |
Why?
|
| Proto-Oncogene Proteins | 2 | 2011 | 645 | 0.090 |
Why?
|
| DNA Mutational Analysis | 1 | 2011 | 526 | 0.090 |
Why?
|
| Tissue Donors | 1 | 2012 | 463 | 0.090 |
Why?
|
| Retrospective Studies | 7 | 2024 | 8477 | 0.080 |
Why?
|
| Drug Evaluation | 1 | 2008 | 141 | 0.080 |
Why?
|
| Combined Modality Therapy | 4 | 2017 | 1685 | 0.080 |
Why?
|
| Gene Expression Regulation, Neoplastic | 2 | 2010 | 1197 | 0.080 |
Why?
|
| Histone Deacetylases | 1 | 2008 | 63 | 0.080 |
Why?
|
| Thiosemicarbazones | 1 | 2008 | 6 | 0.080 |
Why?
|
| Methemoglobinemia | 1 | 2008 | 10 | 0.080 |
Why?
|
| Renal Dialysis | 1 | 2011 | 355 | 0.080 |
Why?
|
| Blood Component Removal | 1 | 2008 | 24 | 0.080 |
Why?
|
| Chimerism | 2 | 2020 | 37 | 0.080 |
Why?
|
| Oligodeoxyribonucleotides | 1 | 2008 | 126 | 0.080 |
Why?
|
| Quinoxalines | 1 | 2008 | 50 | 0.080 |
Why?
|
| DNA (Cytosine-5-)-Methyltransferases | 1 | 2008 | 55 | 0.080 |
Why?
|
| C-Reactive Protein | 1 | 2008 | 190 | 0.080 |
Why?
|
| Acute Kidney Injury | 1 | 2011 | 295 | 0.080 |
Why?
|
| Neoplasm Proteins | 3 | 2020 | 532 | 0.080 |
Why?
|
| Granulocyte Colony-Stimulating Factor | 1 | 2008 | 165 | 0.080 |
Why?
|
| Interleukin-6 | 1 | 2008 | 256 | 0.080 |
Why?
|
| Mycoses | 1 | 2007 | 46 | 0.080 |
Why?
|
| Transplantation, Haploidentical | 2 | 2017 | 27 | 0.070 |
Why?
|
| Karnofsky Performance Status | 1 | 2006 | 40 | 0.070 |
Why?
|
| Histocompatibility Testing | 2 | 2017 | 154 | 0.070 |
Why?
|
| Hematologic Diseases | 2 | 2020 | 79 | 0.070 |
Why?
|
| Proto-Oncogene Proteins c-bcl-2 | 2 | 2023 | 189 | 0.070 |
Why?
|
| Age Factors | 4 | 2013 | 1849 | 0.070 |
Why?
|
| Transcription, Genetic | 1 | 2011 | 1135 | 0.070 |
Why?
|
| Feasibility Studies | 2 | 2008 | 751 | 0.070 |
Why?
|
| Environmental Exposure | 1 | 2008 | 296 | 0.070 |
Why?
|
| Drug Combinations | 2 | 2020 | 224 | 0.070 |
Why?
|
| Survival Rate | 4 | 2014 | 1860 | 0.070 |
Why?
|
| Terminology as Topic | 1 | 2007 | 217 | 0.070 |
Why?
|
| Erythropoietin | 1 | 2005 | 91 | 0.070 |
Why?
|
| Flavonoids | 1 | 2005 | 85 | 0.060 |
Why?
|
| DNA-Binding Proteins | 1 | 2011 | 1208 | 0.060 |
Why?
|
| Androgens | 1 | 2005 | 167 | 0.060 |
Why?
|
| Thalidomide | 2 | 2017 | 54 | 0.060 |
Why?
|
| Societies, Medical | 2 | 2021 | 572 | 0.060 |
Why?
|
| Dairy Products | 1 | 2023 | 11 | 0.060 |
Why?
|
| Interleukin-3 Receptor alpha Subunit | 1 | 2023 | 4 | 0.060 |
Why?
|
| Red Meat | 1 | 2023 | 10 | 0.060 |
Why?
|
| Protein-Tyrosine Kinases | 2 | 2021 | 302 | 0.060 |
Why?
|
| Fatty Acids, Volatile | 1 | 2023 | 32 | 0.060 |
Why?
|
| Transplantation, Autologous | 2 | 2019 | 330 | 0.060 |
Why?
|
| Cyclic AMP Response Element-Binding Protein | 1 | 2023 | 66 | 0.060 |
Why?
|
| Milk | 1 | 2023 | 53 | 0.060 |
Why?
|
| Piperidines | 1 | 2005 | 181 | 0.060 |
Why?
|
| bcl-X Protein | 1 | 2023 | 52 | 0.060 |
Why?
|
| Sheep | 1 | 2023 | 239 | 0.060 |
Why?
|
| Myeloid Cell Leukemia Sequence 1 Protein | 1 | 2023 | 35 | 0.060 |
Why?
|
| Fatigue | 1 | 2004 | 174 | 0.060 |
Why?
|
| Cyclopentanes | 1 | 2023 | 27 | 0.060 |
Why?
|
| Cyclic AMP-Dependent Protein Kinases | 1 | 2023 | 107 | 0.060 |
Why?
|
| Cattle | 1 | 2023 | 376 | 0.060 |
Why?
|
| Social Determinants of Health | 1 | 2024 | 78 | 0.060 |
Why?
|
| Drug Approval | 2 | 2015 | 62 | 0.060 |
Why?
|
| Cell- and Tissue-Based Therapy | 1 | 2023 | 49 | 0.060 |
Why?
|
| Cyclic AMP | 1 | 2023 | 273 | 0.060 |
Why?
|
| Angiogenesis Inhibitors | 1 | 2005 | 311 | 0.060 |
Why?
|
| Clinical Trials, Phase I as Topic | 1 | 2023 | 155 | 0.050 |
Why?
|
| World Health Organization | 1 | 2022 | 103 | 0.050 |
Why?
|
| Phenotype | 2 | 2020 | 2378 | 0.050 |
Why?
|
| Mice, SCID | 1 | 2022 | 252 | 0.050 |
Why?
|
| Prevalence | 2 | 2018 | 1239 | 0.050 |
Why?
|
| Ketoglutaric Acids | 1 | 2021 | 12 | 0.050 |
Why?
|
| Acetyl-CoA C-Acetyltransferase | 1 | 2021 | 7 | 0.050 |
Why?
|
| NADP | 1 | 2021 | 45 | 0.050 |
Why?
|
| Infusions, Intravenous | 2 | 2015 | 429 | 0.050 |
Why?
|
| Primary Cell Culture | 1 | 2021 | 72 | 0.050 |
Why?
|
| Acetylation | 1 | 2021 | 121 | 0.050 |
Why?
|
| Clone Cells | 1 | 2021 | 213 | 0.050 |
Why?
|
| Single-Blind Method | 1 | 2021 | 153 | 0.050 |
Why?
|
| Bone Marrow | 2 | 2016 | 435 | 0.050 |
Why?
|
| Bridged Bicyclo Compounds, Heterocyclic | 1 | 2021 | 76 | 0.050 |
Why?
|
| Pilot Projects | 2 | 2015 | 839 | 0.050 |
Why?
|
| DNA-Cytosine Methylases | 1 | 2020 | 4 | 0.050 |
Why?
|
| Long Interspersed Nucleotide Elements | 1 | 2020 | 12 | 0.050 |
Why?
|
| Capsules | 1 | 2020 | 38 | 0.050 |
Why?
|
| Daunorubicin | 1 | 2020 | 78 | 0.050 |
Why?
|
| Least-Squares Analysis | 1 | 2020 | 48 | 0.050 |
Why?
|
| Lysine | 1 | 2021 | 147 | 0.050 |
Why?
|
| Europe | 1 | 2021 | 309 | 0.050 |
Why?
|
| Drug Synergism | 1 | 2021 | 303 | 0.050 |
Why?
|
| Illinois | 2 | 2012 | 462 | 0.050 |
Why?
|
| Hematopoietic Stem Cell Mobilization | 2 | 2012 | 50 | 0.050 |
Why?
|
| Risk | 2 | 2012 | 674 | 0.050 |
Why?
|
| Health Planning Guidelines | 1 | 2019 | 24 | 0.050 |
Why?
|
| Area Under Curve | 1 | 2020 | 334 | 0.040 |
Why?
|
| Health Plan Implementation | 1 | 2019 | 56 | 0.040 |
Why?
|
| Diamines | 1 | 2019 | 11 | 0.040 |
Why?
|
| Early Detection of Cancer | 2 | 2015 | 392 | 0.040 |
Why?
|
| Cross-Over Studies | 1 | 2020 | 399 | 0.040 |
Why?
|
| Risk Assessment | 2 | 2023 | 2261 | 0.040 |
Why?
|
| Standard of Care | 1 | 2019 | 78 | 0.040 |
Why?
|
| Gastrointestinal Diseases | 1 | 2020 | 146 | 0.040 |
Why?
|
| Tablets | 1 | 2020 | 118 | 0.040 |
Why?
|
| Protein Biosynthesis | 1 | 2021 | 378 | 0.040 |
Why?
|
| Phosphorylation | 1 | 2021 | 1106 | 0.040 |
Why?
|
| Drug Interactions | 1 | 2019 | 248 | 0.040 |
Why?
|
| Polymorphism, Single Nucleotide | 2 | 2021 | 2357 | 0.040 |
Why?
|
| Safety | 1 | 2019 | 152 | 0.040 |
Why?
|
| Preoperative Period | 1 | 2018 | 91 | 0.040 |
Why?
|
| Time Factors | 2 | 2021 | 5209 | 0.040 |
Why?
|
| Lymphocyte Depletion | 1 | 2017 | 97 | 0.040 |
Why?
|
| Palliative Care | 1 | 2019 | 257 | 0.040 |
Why?
|
| Protein Binding | 1 | 2021 | 1456 | 0.040 |
Why?
|
| Clinical Decision-Making | 1 | 2019 | 257 | 0.040 |
Why?
|
| Cause of Death | 1 | 2018 | 277 | 0.040 |
Why?
|
| Postoperative Complications | 1 | 2007 | 2207 | 0.040 |
Why?
|
| Predictive Value of Tests | 2 | 2014 | 1673 | 0.040 |
Why?
|
| Apoptosis | 1 | 2023 | 1683 | 0.040 |
Why?
|
| Nuclear Proteins | 1 | 2021 | 696 | 0.040 |
Why?
|
| Incidence | 2 | 2011 | 1577 | 0.040 |
Why?
|
| Retreatment | 1 | 2016 | 107 | 0.040 |
Why?
|
| Pain, Procedural | 1 | 2016 | 3 | 0.040 |
Why?
|
| Ranitidine | 1 | 2016 | 8 | 0.040 |
Why?
|
| Chemotherapy-Induced Febrile Neutropenia | 1 | 2016 | 6 | 0.030 |
Why?
|
| Anti-Ulcer Agents | 1 | 2016 | 22 | 0.030 |
Why?
|
| Histocompatibility | 1 | 2016 | 71 | 0.030 |
Why?
|
| U937 Cells | 1 | 2015 | 32 | 0.030 |
Why?
|
| Organ Size | 1 | 2016 | 364 | 0.030 |
Why?
|
| Pemetrexed | 1 | 2016 | 76 | 0.030 |
Why?
|
| Leukocyte Count | 1 | 2016 | 220 | 0.030 |
Why?
|
| Patient Selection | 1 | 2019 | 685 | 0.030 |
Why?
|
| Immunosuppressive Agents | 2 | 2011 | 977 | 0.030 |
Why?
|
| Liver Function Tests | 1 | 2015 | 93 | 0.030 |
Why?
|
| Gene Expression Regulation, Leukemic | 1 | 2015 | 90 | 0.030 |
Why?
|
| Financing, Government | 1 | 2015 | 23 | 0.030 |
Why?
|
| Federal Government | 1 | 2015 | 29 | 0.030 |
Why?
|
| Neoplasm Grading | 1 | 2016 | 357 | 0.030 |
Why?
|
| Carboplatin | 1 | 2016 | 286 | 0.030 |
Why?
|
| Anemia | 1 | 2016 | 128 | 0.030 |
Why?
|
| Leukocytes, Mononuclear | 1 | 2016 | 196 | 0.030 |
Why?
|
| Mortality | 1 | 2016 | 149 | 0.030 |
Why?
|
| Rare Diseases | 1 | 2015 | 59 | 0.030 |
Why?
|
| Bone Marrow Cells | 1 | 2016 | 253 | 0.030 |
Why?
|
| Pandemics | 1 | 2021 | 740 | 0.030 |
Why?
|
| Research Support as Topic | 1 | 2015 | 80 | 0.030 |
Why?
|
| Neutrophils | 1 | 2016 | 307 | 0.030 |
Why?
|
| United States Food and Drug Administration | 1 | 2015 | 127 | 0.030 |
Why?
|
| beta Catenin | 1 | 2016 | 251 | 0.030 |
Why?
|
| Antineoplastic Agents, Hormonal | 1 | 2015 | 150 | 0.030 |
Why?
|
| Tumor Cells, Cultured | 1 | 2015 | 1041 | 0.030 |
Why?
|
| RNA, Small Interfering | 1 | 2015 | 547 | 0.030 |
Why?
|
| Platelet Count | 1 | 2013 | 92 | 0.030 |
Why?
|
| Proportional Hazards Models | 2 | 2006 | 858 | 0.030 |
Why?
|
| Cancer Vaccines | 1 | 2015 | 156 | 0.030 |
Why?
|
| T-Lymphocytes | 1 | 2020 | 1195 | 0.030 |
Why?
|
| Immunoglobulin Isotypes | 1 | 2013 | 32 | 0.030 |
Why?
|
| Pneumococcal Vaccines | 1 | 2013 | 28 | 0.030 |
Why?
|
| Receptors, Vascular Endothelial Growth Factor | 1 | 2013 | 70 | 0.030 |
Why?
|
| Translocation, Genetic | 1 | 2014 | 265 | 0.030 |
Why?
|
| Lymphocyte Subsets | 1 | 2013 | 64 | 0.030 |
Why?
|
| Lymphocyte Count | 1 | 2013 | 94 | 0.030 |
Why?
|
| Alleles | 1 | 2016 | 1128 | 0.030 |
Why?
|
| Virus Diseases | 1 | 2013 | 97 | 0.030 |
Why?
|
| Patient Outcome Assessment | 1 | 2013 | 84 | 0.030 |
Why?
|
| Drugs, Investigational | 1 | 2012 | 37 | 0.030 |
Why?
|
| Vascular Diseases | 1 | 2013 | 121 | 0.030 |
Why?
|
| Multicenter Studies as Topic | 1 | 2012 | 159 | 0.030 |
Why?
|
| Adult Stem Cells | 1 | 2011 | 30 | 0.030 |
Why?
|
| Hospice Care | 1 | 2011 | 39 | 0.030 |
Why?
|
| Child | 2 | 2014 | 6926 | 0.030 |
Why?
|
| Interferon-alpha | 1 | 2012 | 233 | 0.030 |
Why?
|
| DNA, Neoplasm | 1 | 2012 | 265 | 0.020 |
Why?
|
| Secondary Prevention | 1 | 2011 | 162 | 0.020 |
Why?
|
| Educational Status | 1 | 2011 | 188 | 0.020 |
Why?
|
| Primary Prevention | 1 | 2011 | 85 | 0.020 |
Why?
|
| Diarrhea | 1 | 2012 | 182 | 0.020 |
Why?
|
| Double-Blind Method | 1 | 2015 | 1823 | 0.020 |
Why?
|
| Fatal Outcome | 1 | 2011 | 293 | 0.020 |
Why?
|
| Metabolic Clearance Rate | 1 | 2010 | 121 | 0.020 |
Why?
|
| Radiotherapy, Adjuvant | 1 | 2011 | 291 | 0.020 |
Why?
|
| Receptors, Antigen, T-Cell | 1 | 2013 | 372 | 0.020 |
Why?
|
| Health Care Reform | 1 | 2011 | 90 | 0.020 |
Why?
|
| Nervous System Diseases | 1 | 2011 | 151 | 0.020 |
Why?
|
| Research | 1 | 2011 | 253 | 0.020 |
Why?
|
| Family | 1 | 2012 | 311 | 0.020 |
Why?
|
| Liver | 1 | 2015 | 1230 | 0.020 |
Why?
|
| Chemotherapy, Adjuvant | 1 | 2011 | 468 | 0.020 |
Why?
|
| Glomerular Filtration Rate | 1 | 2011 | 384 | 0.020 |
Why?
|
| Tacrolimus | 1 | 2011 | 373 | 0.020 |
Why?
|
| Health Policy | 1 | 2011 | 180 | 0.020 |
Why?
|
| Polyethylene Glycols | 1 | 2012 | 363 | 0.020 |
Why?
|
| Lymphoma, Non-Hodgkin | 1 | 2011 | 261 | 0.020 |
Why?
|
| Follow-Up Studies | 1 | 2016 | 3636 | 0.020 |
Why?
|
| Down-Regulation | 1 | 2010 | 504 | 0.020 |
Why?
|
| Myeloablative Agonists | 1 | 2008 | 34 | 0.020 |
Why?
|
| DNA (Cytosine-5-)-Methyltransferase 1 | 1 | 2008 | 18 | 0.020 |
Why?
|
| Half-Life | 1 | 2008 | 96 | 0.020 |
Why?
|
| Stereoisomerism | 1 | 2008 | 102 | 0.020 |
Why?
|
| Filgrastim | 1 | 2008 | 56 | 0.020 |
Why?
|
| Health Services Accessibility | 1 | 2011 | 394 | 0.020 |
Why?
|
| Obesity | 1 | 2015 | 963 | 0.020 |
Why?
|
| Treatment Failure | 1 | 2008 | 285 | 0.020 |
Why?
|
| Practice Guidelines as Topic | 1 | 2015 | 1034 | 0.020 |
Why?
|
| Infant | 1 | 2014 | 3045 | 0.020 |
Why?
|
| Healthcare Disparities | 1 | 2011 | 370 | 0.020 |
Why?
|
| Child, Preschool | 1 | 2014 | 3611 | 0.020 |
Why?
|
| Antifungal Agents | 1 | 2007 | 117 | 0.020 |
Why?
|
| Liver Diseases | 1 | 2008 | 238 | 0.020 |
Why?
|
| Inflammation | 1 | 2012 | 920 | 0.020 |
Why?
|
| Infusion Pumps | 1 | 2005 | 25 | 0.020 |
Why?
|
| Length of Stay | 1 | 2008 | 700 | 0.020 |
Why?
|
| Gene Expression Profiling | 1 | 2011 | 1384 | 0.020 |
Why?
|
| MicroRNAs | 1 | 2010 | 534 | 0.020 |
Why?
|
| Biological Availability | 1 | 2004 | 92 | 0.020 |
Why?
|
| Statistics, Nonparametric | 1 | 2004 | 307 | 0.020 |
Why?
|
| Prostatic Neoplasms | 1 | 2015 | 1721 | 0.010 |
Why?
|
| Genome-Wide Association Study | 1 | 2011 | 1621 | 0.010 |
Why?
|
| Blotting, Western | 1 | 2004 | 782 | 0.010 |
Why?
|
| Genetic Predisposition to Disease | 1 | 2011 | 2270 | 0.010 |
Why?
|
| Analysis of Variance | 1 | 2004 | 912 | 0.010 |
Why?
|
| RNA, Messenger | 1 | 2008 | 1981 | 0.010 |
Why?
|
| Tomography, X-Ray Computed | 1 | 2011 | 2601 | 0.010 |
Why?
|
| Breast Neoplasms | 1 | 2015 | 2887 | 0.010 |
Why?
|